Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tecartus
Pharma
FDA OKs BMS' Breyanzi as first CAR-T for marginal zone lymphoma
With FDA approval to treat marginal zone lymphoma, BMS’ Breyanzi has become the first CAR-T therapy for the patient population.
Kevin Dunleavy
Dec 5, 2025 11:00am
Gilead reports 7% sales decline for CAR-Ts Yescarta, Tecartus
Aug 8, 2025 11:40am
FDA removes barrier to CAR-Ts; move likely to boost uptake
Jun 27, 2025 11:14am
Gilead's CAR-T sales stagnate as Trodelvy takes another write-off
Nov 7, 2024 11:16am
FDA revisits CAR-T boxed warning on secondary cancers: Marks
Nov 1, 2024 10:30am
Gilead's at 'just the beginning' of cell therapy movement: exec
Feb 7, 2024 2:08pm
